Elizabeth Plimack MD
@ERPlimackMD
Followers
7K
Following
19K
Media
407
Statuses
4K
Deputy Director @FoxChaseCancer. Professor GU Med Onc. @ASCO BOD 2020-24. Views mine. COI: https://t.co/fmmRpMCIWd
Fox Chase Cancer Center
Joined May 2014
Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top.
4
33
78
RT @DrYukselUrun: KEYNOTE905: #Pembrolizumab + #EnfortumabVedotin before & after cystectomy improved EFS, OS & pCR vs surgery alone. A new….
0
43
0
RT @Dr_RaviMadan: Important to distinguish #serosal findings on #PSMA 🩻vs. #parenchymal. Serosal lesions are better seen on #PSMA vs CT/MRI….
0
11
0
RT @mirrorsmed: Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic….
0
10
0
RT @crisbergerot: Excited to share our new paper @EurUrolOncol! 🎉 We developed patient-centered, stage-specific FKSI-23 tools to better cap….
0
36
0
RT @arkhaki: Exciting to see the trial I wrote at @ASCO @AACR #VailWorkshop2019 published. Thanks to mentor @PGrivasMDPhD and for the team….
0
16
0
RT @urotoday: Evolving first-line and maintenance strategies in #UrothelialCancer: Insights from #ASCO25. Jacqueline Brown, MD @WinshipAtEm….
0
4
0
RT @ASCO: 🎙 New host @montypal of @cityofhope and @KimmieNgMD of @danafarber @DFarberYoungCRC discuss the alarming rise of early-onset GI c….
0
11
0
RT @GUconference: Just 2 weeks to go! Curious how leading experts are applying MRD in real-world GU cancer care? Don’t miss this high-impac….
0
3
0
RT @BladderCancerUS: PLEASE SHARE -> ICYMI, BCAN has created a fund of up to $1 million to help BC researchers whose federal funding has be….
0
16
0
RT @KidneyCancer: 🎊 Abstract Submissions for #IKCSNA25 are Open! 🎊. Join the KCA on Nov 13-15 in Denver, CO for the 2025 IKCS: North Americ….
0
7
0
RT @KidneyCancer: 👩⚕️ Are you a woman physician or researcher working in #kidneycancer? Our Women in RCC Virtual Coaching Program offers e….
0
4
0
RT @KidneyCancer: 🚨 Applications are OPEN!. KCA is investing in the next generation of #KidneyCancer leaders through TWO unique mentorship….
0
5
0
RT @KidneyCancer: One month left to register for KCA's Women in RCC summer webinar! Join a conversation with @KimrynRathmell @OSUCCC_James….
0
3
0
RT @urotoday: EV-302 data: High CR rates and long-term survival with EV-pembro. @shilpaonc @ClevelandClinic joins @ERPlimackMD @FoxChaseCan….
0
1
0
RT @GUconference: Can ctDNA help us better define MRD in bladder cancer? Dr. @ERPlimackMD will explore this evolving space at #WorldGU25 in….
0
2
0
RT @FoxChaseCancer: @ERPlimackMD is joined by Andrea Necchi to discuss the SURE-02 trial, evaluating sacituzumab govitecan plus pembrolizum….
urotoday.com
Elizabeth Plimack is joined by Andrea Necchi to discuss the SURE-02 trial, evaluating sacituzumab govitecan plus pembrolizumab in a bladder-sparing approach for muscle-invasive bladder cancer....
0
1
0
RT @KidneyCancer: 🎉 We're so excited to have @KimrynRathmell @OSUCCC_James join us in conversation during the KCA's Women in RCC summer web….
0
7
0
RT @shilpaonc: #ASCO25 Was humbled to see a patient approach me on the heels of our presentation yesterday & sharing his experience of achi….
0
10
0